Abstract
The c-myc oncogene acts as a pluripotent modulator of transcription during normal cell growth and proliferation. Deregulated c-myc activity in cancer can lead to excessive activation of its downstream pathways, and may also stimulate changes in gene expression and cellular signaling that are not observed under non-pathological conditions. Under certain conditions, aberrant c-myc activity is associated with the appearance of DNA damage-associated markers and karyotypic abnormalities. In this chapter, we discuss mechanisms by which c-myc may be directly or indirectly associated with the induction of genomic instability. The degree to which c-myc-induced genomic instability influences the initiation or progression of cancer is likely to depend on other factors, which are discussed herein.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
References
Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235–248
Bodmer WF, Tomlinson I (1996) Population genetics of tumours. Ciba Found Symp 197:181–189; discussion 189–193
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Potter M, Melchers F (eds) (1997) Proceedings of the 14th Mechanisms in B-cell Neoplasia meeting. Bethesda, Maryland, 21–23 October 21–23 1996. Current Topics in Microbiology and Immunology, vol 224. Springer-Verlag, Heidelberg Berlin New York, pp 1–291
Watson PH, Singh R, Hole AK (1996) Influence of c-myc on the progression of human breast cancer. In: Gunthert U, Birchmeier B (eds) Current Topics in Microbiology and Immunology, vol 213. Springer-Verlag, Heidelberg Berlin New York, pp 267–283
Mushinski JF, Hanley-Hyde J, Rainey GJ, Kuschak TI, Taylor C, Fluri M, Stevens LM, Henderson DW, Mai S (1999) Myc-induced cyclin D2 genomic instability in murine B cell neoplasms. In: Melchers F, Potter M (eds) Current Topics in Microbiology and Immunology, vol 246. Springer-Verlag, Heidelberg Berlin New York, pp 183–189; discussion 190–192
Eisenman RN (2001) Deconstructing myc. Genes Dev 15:2023–2030
Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: MarvelouslY complex. Adv Cancer Res 84:81–154
Lutz W, Leon J, Eilers M (2002) Contributions of Myc to tumorigenesis. Biochim Biophys Acta 1602:61–71
Pelengaris S, Khan M, Evan G (2002) c-myc: more than just a matter of life and death. Nat Rev Cancer 2:764–776
Armitage P, Doll R (1954) The age distribution of cancer and multistage theory of carcinogenesis. Br J Cancer 8:1–12
Tomlinson I, Bodmer W (1999) Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med 5:11–12
Loeb KR, Loeb LA (2000) Significance of multiple mutations in cancer. Carcinogenesis 21:379–385
Savelyeva L, Schwab M (2001) Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett 167:115–123
Popescu NC, Zimonjic DB (2002) Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med 6:151–159
Wright JA, Smith HS, Watt FM, Hancock MC, Hudson DL, Stark GR (1990) DNA amplification is rare in normal human cells. Proc Natl Acad Sci USA 87:1791–1795
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948
Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386:623–627
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561
Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816–819
Jallepalli PV, Lengauer C (2001) Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 1:109–117
Klein G (1999) Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. In: Melchers F, Potter M (eds) Current Topics in Microbiology and Immunology, vol 246. Springer-Verlag, Heidelberg Berlin New York, pp 161–167
Stark GR (1993) Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 61:87–113
Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, Hamilton SR, Kinzler KW, Vogelstein B (1995) Mismatch repair deficiency in phenotypically normal human cells. Science 268:738–740
Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038
Wright WE, Shay JW (2001) Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev 11:98–103
Hickman JA (2002) Apoptosis and tumourigenesis. Curr Opin Genet Dev 12:67–72
Balmain A, Harris CC (2000) Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 21:371–377
Ross JA, Nesnow S (1999) Polycyclic aromatic hydrocarbons: correlations between DNA adducts and ras oncogene mutations. Mutat Res 424:155–166
Bos JL (1988) The ras gene family and human carcinogenesis. Mutat Res 195:255–271
Balmain A, Brown K (1988) Oncogene activation in chemical carcinogenesis. Adv Cancer Res 51:147–182
Nichols WW (1963) Relationships of viruses, chromosomes and carcinogenesis. Hereditas 50:53–80
Nowell PC (1965) Chromosome changes in primary tumors. Prog Exp Tumor Res 7:83–103
Loeb LA, Springgate CF, Battula N (1974) Errors in DNA replication as a basis of malignant changes. Cancer Res 34:2311–2321
Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258–261
Duval A, Hamelin R (2002) Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 62:2447–2454
Hussein MR, Sun M, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky O (2002) Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 34:35–44
Simpson AJ, Caballero OL, Pena SD (2001) Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med 7:76–80
Nichols WW, Levan A, Heneen WK, Peluse M (1965) Synergism of the Schmidt-Ruppin strain of the Rous sarcoma virus and cytidine triphosphate in the induction of chromosome breaks in human cultured leukocytes. Hereditas 54:213–236
Stehelin D, Guntaka RV, Varmus HE, Bishop JM (1976) Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. J Mol Biol 101:349–365
Nanus DM, Lynch SA, Rao PH, Anderson SM, Jhanwar SC, Albino AP (1991) Transformation of human kidney proximal tubule cells by a src-containing retrovirus. Oncogene 6:2105–2111
Neil JC, Cameron ER (2002) Retroviral insertion sites and cancer: fountain of all knowledge? Cancer Cell 2:253–255
Tsichlis PN (1987) Oncogenesis by Moloney murine leukemia virus. Anticancer Res 7:171–180
Hsu T, Moroy T, Etiemble J, Louise A, Trepo C, Tiollais P, Buendia MA (1988) Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell 55:627–635
Kim R, Trubetskoy A, Suzuki T, Jenkins NA, Copeland NG, Lenz J (2003) Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J Virol 77:2056–2062
zur Hausen H (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9–13
Bibbo M, Montag AG, Lerma-Puertas E, Dytch HE, Leelakusolvong S, Bartels PH (1989) Karyometric marker features in tissue adjacent to invasive cervical carcinomas. Anal Quant Cytol Histol 11:281–285
Munger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89:213–228
White AE, Livanos EM, Tlsty TD (1994) Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8:666–677
Duensing S, Munger K (2002) The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 62:7075–7082
Windle B, Draper BW, Yin YX, O’Gorman S, Wahl GM (1991) A central role for chromosome breakage in gene amplification deletion formation, and amplicon integration. Genes Dev 5:160–174
Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ (1994) The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 91:5124–5128
Fukasawa K, Vande Woude GF (1997) Synergy between theMos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 17:506–518
Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, Fearon ER (2000) γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev 14:1319–1331
van Es JH, Barker N, Clevers H (2003) You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 13:28–33
Boxer LM, Dang CV (2001) Translocations involving c-myc and c-myc function. Oncogene 20:5595–5610
Bahram F, von der Lehr N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95:2104–2110
Gregory MA, Hann SR (2000) c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt’s lymphoma cells. Mol Cell Biol 20:2423–2435
Bonilla M, Ramirez M, Lopez-Cueto J, Gariglio P (1988) In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80:665–671
Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A 83:4834–4838
Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, Watson J (1987) c-myc oncogene expression in colorectal cancer. Cancer 59:1289–1295
Smith DR, Myint T, Goh HS (1993) Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 68:407–413
Stewart J, Evan G, Watson J, Sikora K (1986) Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer 53:1–6
Nagy P, Evarts RP, Marsden E, Roach J, Thorgeirsson SS (1988) Cellular distribution of c-myc transcripts during chemical hepatocarcinogenesis in rats. Cancer Res 48:5522–5527
Sargent LM, Sanderson ND, Thorgeirsson SS (1996) Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes. Cancer Res 56:2137–2142
McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB (1998) Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 16:2755–2766
Fearon ER, Gruber SB (2001) Molecular abnormalities in colon and rectal cancer. In: Mendelson J, Howley PM, Israel MA, Liotta LA (eds) The molecular basis of cancer. W.B. Saunders, Philadelphia, pp 289–312
Denis N, Kitzis A, Kruh J, Dautry F, Corcos D (1991) Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc. Oncogene 6:1453–1457
Mai S (1994) Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. Gene 148:253–260
Mai S, Hanley-Hyde J, Fluri M (1996) c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene 12:277–288
Felsher DW, Bishop JM (1999) Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A 96:3940–3944
Mai S, Hanley-Hyde J, Rainey GJ, Kuschak TI, Paul JT, Littlewood TD, Mischak H, Stevens LM, Henderson DW, Mushinski JF (1999) Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. Neoplasia 1:241–252
Kuschak TI, Taylor C, McMillan-Ward E, Israels S, Henderson DW, Mushinski JF, Wright JA, Mai S (1999) The ribonucleotide reductase R2 gene is anon-transcribed target of c-Myc-induced genomic instability. Gene 238:351–365
Paulson TG, Almasan A, Brody LL, Wahl GM (1998) Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol 18:3089–3100
Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW (2003) Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101:2797–2803
Hynes NE (1993) Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4:19–26
Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB (1992) Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980–2983
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83
Sargent LM, Zhou X, Keck CL, Sanderson ND, Zimonjic DB, Popescu NC, Thorgeirsson SS (1999) Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol 154:1047–1055
Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533–538
Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC 3rd (2000) Burkitt lymphoma in the mouse. J Exp Med 192:1183–1190
Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670–2677
Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL (2001) Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21:7653–7662
Strasser A, Harris AW, Bath ML, Cory S (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331–333
Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289–298
Rockwood LD, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, Ried T, Morse HC 3rd, Janz S (2002) Genomic instability in mouse Burkitt lymphoma is dominatedby illegitimate genetic recombinations, not point mutations. Oncogene 21:7235–7240
Lindstrom MS, Wiman KG (2002) Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12:381–387
Schimke RT (1986) Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer 57:1912–1917
Schimke RT, Sherwood SW, Hill AB, Johnston RN (1986) Overreplication and recombination of DNA in higher eukaryotes: potential consequences and biological implications. Proc Natl Acad Sci U S A 83:2157–2161
Windle BE, Wahl GM (1992) Molecular dissection of mammalian gene amplification: new mechanistic insights revealed by analyses of very early events. Mutat Res 276:199–224
Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, Dutta A (2003) A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 11:997–1008
Watson JD, Oster SK, Shago M, Khosravi F, Penn LZ (2002) Identifying genes regulated in a Myc-dependent manner. J Biol Chem 277:36921–36930
Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B (2003) Genomic targets of the human c-Myc protein. Genes Dev 17:1115–1129
Smith KA, Agarwal ML, Chernov MV, Chernova OB, Deguchi Y, Ishizaka Y, Patterson TE, Poupon MF, Stark GR (1995) Regulation and mechanisms of gene amplification. Philos Trans R Soc Lond B Biol Sci 347:49–56
Galloway SM (1994) Chromosome aberrations induced in vitro: mechanisms, delayed expression, and intriguing questions. Environ Mol Mutagen 23Suppl 24:44–53
Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM (2002) c-Myc can induce DNA damage increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9:1031–1044
Felsher DW, Zetterberg A, Zhu J, Tlsty T, Bishop JM (2000) Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A 97:10544–10548
Snow EC (1997) The role of c-myc during normal B cell proliferation, and as B cells undergo malignant transformation. In: Potter M, Melchers F (eds) Current Topics in Microbiology and Immunology, vol 224. Springer-Verlag, Heidelberg Berlin New York, pp 211–220
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 98:7319–7324
Courtneidge SA (2002) Role of Src in signal transduction pathways. The Jubilee Lecture. Biochem Soc Trans 30:11–17
Iritani BM, Eisenman RN (1999) c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci U S A 96:13180–13185
Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, Eick D, Kohlhuber F (1999) Control of cell growth by c-Myc in the absence of cell division. Curr Biol 9:1255–1258
Gomez-Roman N, Grandori C, Eisenman RN, White RJ (2003) Direct activation of RNA polymerase III transcription by c-Myc. Nature 421:290–294
O’Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, Mateyak MK, Sedivy JM (2003) A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 278:12563–12573
Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 94:6658–6663
Helbock HJ, Beckman KB, Shigenaga MK, Walter PB, Woodall AA, Yeo HC, Ames BN (1998) DNA oxidation matters: the HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine. Proc Natl Acad Sci U S A 95:288–293
Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275:1649–1652
Yang JQ, Li S, Huang Y, Zhang HJ, Domann FE, Buettner GR, Oberley LW (2001) V-Ha-Ras overexpression induces superoxide production and alters levels of primary antioxidant enzymes. Antioxid Redox Signal 3:697–709
Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9:1017–1029
Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW (2003) Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A 100(17):9974–9979
Xu Y, Nguyen Q, Lo DC, Czaja MJ (1997) c-myc-Dependent hepatoma cell apoptosis results from oxidative stress and not a deficiency of growth factors. J Cell Physiol 170:192–199
Linke SP, Clarkin KC, Wahl GM (1997) p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res 57:1171–1179
Chen Q, Ames BN (1994) Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A 91:4130–4134
Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458–460
Matsui A, Ikeda T, Enomoto K, Hosoda K, Nakashima H, Omae K, Watanabe M, Hibi T, Kitajima M (2000) Increased formation of oxidative DNA damage 8-hydroxy-2′-deoxyguanosine, in human breast cancer tissue and its relationship to GSTP1 and COMT genotypes. Cancer Lett 151:87–95
Gupta A, Rosenberger SF, Bowden GT (1999) Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis 20:2063–2073
Feig DI, Reid TM, Loeb LA (1994) Reactive oxygen species in tumorigenesis. Cancer Res 54:1890s–1894s
Shibutani S, Takeshita M, Grollman AP (1991) Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349:431–434
Rodin SN, Rodin AS (2000) Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci U S A 97:12244–12249
Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J Biol Chem 267:166–172
Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel LJ, Wogan GN, Hofseth LJ, Shields PG, Billiar TR, Trautwein C, Hohler T, Galle PR, Phillips DH, Markin R, Marrogi AJ, Harris CC (2000) Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci U S A 97:12770–12775
Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60:3333–3337
Jackson AL, Chen R, Loeb LA (1998) Induction of microsatellite instability by oxidative DNA damage. Proc Natl Acad Sci U S A 95:12468–12473
Jackson AL, Loeb LA (2000) Microsatellite instability induced by hydrogen peroxide in Escherichia coli. Mutat Res 447:187–198
Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, Zheng S, Willson JK, Markowitz SD, Morin P, Kinzler KW, Vogelstein B, Dunlop MG (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A 93:9049–9054
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336–1338
Gasche C, Chang CL, Rhees J, Goel A, Boland CR (2001) Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res 61:7444–7448
Zienolddiny S, Ryberg D, Haugen A (2000) Induction of microsatellite mutations by oxidative agents in human lung cancer cell lines. Carcinogenesis 21:1521–1526
Muir CS, Wagner G, Demaret E, Nagy-Tiborcz A, Schlaefer K, Villhauer-Lehr M, Whelan S (1982) Directory of on-going research in cancer epidemiology 1982. IARC Sci Publ, Lyon, pp 1–715
Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS (1993) Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 53:1719–1723
Factor VM, Kiss A, Woitach JT, Wirth PJ, Thorgeirsson SS (1998) Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem 273:15846–15853
Factor VM, Laskowska D, Jensen MR, Woitach JT, Popescu NC, Thorgeirsson SS (2000) Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci U S A 97:2196–2201
Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, Bishop JM (2001) c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 414:768–773
Mateyak MK, Obaya AJ, Adachi S, Sedivy JM (1997) Phenotypes of c-Myc-deficient rat fibroblasts isolatedby targeted homologous recombination. Cell Growth Differ 8:1039–1048
Blagosklonny MV, Pardee AB (2002) The restriction point of the cell cycle. Cell Cycle 1:103–110
Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053–1061
Weintraub SJ, Chow KN, Luo RX, Zhang SH, He S, Dean DC (1995)Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375:812–815
Beier R, Burgin A, Kiermaier A, Fero M, Karsunky H, Saffrich R, Moroy T, Ansorge W, Roberts J, Eilers M (2000) Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. EMBO J 19:5813–5823
Mateyak MK, Obaya AJ, Sedivy JM (1999) c-Myc regulates cyclin D-Cdk4 and-Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 19:4672–4683
Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J (2000) Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 20:3497–3509
Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A (2000) Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407:592–598
Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, Giangrande P, Wu L, Saavedra HI, Field SJ, Thompson MA, Yang H, Fujiwara Y, Greenberg ME, Orkin S, Smith C, Nevins JR (2001) Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 8:105–113
Dulic V, Lees E, Reed SI (1992) Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257:1958–1961
Hatakeyama M, Brill JA, Fink GR, Weinberg RA (1994)Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 8:1759–1771
Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA (1992) Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993–1006
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231–234
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227–230
Martins CP, Berns A (2002) Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J 21:3739–3748
Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M (1999) Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13:1181–1189
Vlach J, Hennecke S, Amati B (1997) Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16:5334–5344
Nguyen H, Gitig DM (1999) Koff Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 19:1190–1201
Carrano AC, Eytan E, Hershko A, Pagano M (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193–199
Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H (1999) p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9:661–664
O’Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin WG Jr, DePinho RA (2000) Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 14:2185–2191
Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B (1996) Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 15:6595–6604
Alevizopoulos K, Vlach J, Hennecke S, Amati B (1997) Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J 16:5322–5333
Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300
Walter J, Sun L, Newport J (1998) Regulated chromosomal DNA replication in the absence of a nucleus. Mol Cell 1:519–529
Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ (1998) Centrosome defects and genetic instability in malignant tumors. Cancer Res 58:3974–3985
Hua XH, Yan H, Newport J (1997) A role for Cdk2 kinase in negatively regulating DNA replication during S phase of the cell cycle. J Cell Biol 137:183–192
Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES (2002) Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 277:44376–44384
Lengronne A, Schwob E (2002) The yeast CDK inhibitor Sic1 prevents genomic instability by promoting replication origin licensing in late G(1). Mol Cell 9:1067–1078
Nyberg KA, Michelson RJ, Putnam CW, Weinert TA (2002) Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36:617–656
Huang LC, Clarkin KC, Wahl GM (1996) Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A 93:4827–4832
Wahl GM, Carr AM (2001) The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3:E277–E286
D’Amours D, Jackson SP (2002) The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol 3:317–327
Mirzoeva OK, Petrini JH (2001) DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol Cell Biol 21:281–288
Petrini JH (1999) The mammalian Mre11-Rad50-nbs1 protein complex: integration of functions in the cellular DNA-damage response. Am J Hum Genet 64:1264–1269
Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499–506
Mirzoeva OK, Petrini JH (2003) DNA replication-dependent nuclear dynamics of the mre11 complex. Mol Cancer Res 1:207–218
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674–1677
Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ (2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 97:10389–10394
Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273:33048–33053
Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18:1805–1814
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816
Sheen JH, Dickson RB (2002) Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol Cell Biol 22:1819–1833
Hermeking H, Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265:2091–2093
Seoane J, Le HV, Massague J (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729–734
Li Q, Dang CV (1999) c-Myc overexpression uncouples DNA replication from mitosis. Mol Cell Biol 19:5339–5351
Shim J, Lee H, Park J, Kim H, Choi EJ (1996) A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381:804–806
Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S (1999) Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18:1223–1234
Di Leonardo A, Linke SP, Clarkin K, Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540–2551
Allan LA, Duhig T, Read M, Fried M (2000) The p21(WAF1/CIP1) promoter is methylated in Rat-1 cells: stable restoration of p53-dependent p21(WAF1/CIP1) expression after transfection of a genomic clone containing the p21(WAF1/CIP1) gene. Mol Cell Biol 20:1291–1298
Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE (2002) p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 12:1817–1827
Nasmyth K (2002) Segregating sister genomes: the molecular biology of chromosome separation. Science 297:559–565
Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI (1998) Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18:629–643
Bates S, Ryan KM, Phillips AC, Vousden KH (1998) Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. Oncogene 17:1691–1703
Stewart ZA, Leach SD, Pietenpol JA (1999) p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol 19:205–215
Andreassen PR, Margolis RL (1994) Microtubule dependency of p34cdc2 inactivation and mitotic exit in mammalian cells. J Cell Biol 127:789–802
Khan SH, Wahl GM (1998) p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 58:396–401
Kung AL, Sherwood SW, Schimke RT (1990) Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA 87:9553–9557
Lanni JS, Jacks T (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055–1064
Minn AJ, Boise LH, Thompson CB (1996) Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev 10:2621–2631
Pourquier P, Pommier Y (2001) Topoisomerase I-mediated DNA damage. Adv Cancer Res 80:189–216
Zhu J, Schiestl RH (1996) Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol 16:1805–1812
Labib K, Diffley JF (2001) Is the MCM2-7 complex the eukaryotic DNA replication fork helicase? Curr Opin Genet Dev 11:64–70
Chiang YC, Teng SC, Su YN, Hsieh FJ, Wu KJ (2003) c-MYC directly regulates the transcription of NBS1 gene involved in DNA double-strand break repair. J Biol Chem 13:13
Schorl C, Sedivy JM (2003) Loss of protooncogene c-Myc function impedes G(1) phase progression both before and after the restriction point. Mol Biol Cell 14:823–835
Williams BR, Mirzoeva OK, Morgan WF, Lin J, Dunnick W, Petrini JH (2002) A murine model of Nijmegen breakage syndrome. Curr Biol 12:648–653
Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, Moser MJ, Oshima J, Russell DW, Swisshelm K, Frank S, Amati B, Dalla-Favera R, Monnat RJ Jr (2003) Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 17:1569–1574
Schar P (2001) DNA damage genome instability Spontaneous, and cancer-when DNA replication escapes control. Cell 104:329–332
Loeb LA (2001) A mutator phenotype in cancer. Cancer Res 61:3230–3239
Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199–207
Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3:565–577
Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109:321–334
D’Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7:235–239
Ilyas M, Straub J, Tomlinson IP, Bodmer WF (1999) Genetic pathways in colorectal and other cancers. Eur J Cancer 35:1986–2002
Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ (2001) WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 20:5810–5817
Smalley MJ, Dale TC (1999) Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 18:215–230
You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, Evan G, Kitajewski J, Wang CY (2002) Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157:429–440
Smalley MJ, Dale TC (2001) Wnt signaling and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 6:37–52
Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17:488–501
Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102–104
Arnold I, Watt FM (2001) c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 11:558–568
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wade, M., Wahl, G.M. (2006). c-Myc, Genome Instability, and Tumorigenesis: The Devil Is in the Details. In: Eisenman, R.N. (eds) The Myc/Max/Mad Transcription Factor Network. Current Topics in Microbiology and Immunology, vol 302. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-32952-8_7
Download citation
DOI: https://doi.org/10.1007/3-540-32952-8_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23968-0
Online ISBN: 978-3-540-32952-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)